Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2407189 | Vaccine | 2009 | 8 Pages |
Abstract
Currently, more than half of the world's population has no immunity against smallpox variola major virus. This phase I double-blind, randomized trial was conducted to compare the safety and immunogenicity of two clonally derived, cell-culture manufactured vaccinia strains, ACAM1000 and ACAM2000, to the parent vaccine, Dryvax®. Thirty vaccinia-naïve subjects were enrolled into each of three groups and vaccines were administered percutaneously using a bifurcated needle at a dose of 1.0 × 108 PFU/mL. All subjects had a primary skin reaction indicating a successful vaccination. The adverse events, 4-fold neutralizing antibody rise and T cell immune responses were similar between the groups.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sharon E. Frey, Frances K. Newman, Jeffrey S. Kennedy, Francis Ennis, Getahun Abate, Daniel F. Hoft, Thomas P. Monath,